News coverage about Vital Therapies (NASDAQ:VTL) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vital Therapies earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.697547598997 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of brokerages have issued reports on VTL. Zacks Investment Research cut shares of Vital Therapies from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. ValuEngine raised shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a report on Wednesday, March 28th. BidaskClub raised shares of Vital Therapies from a “hold” rating to a “buy” rating in a report on Wednesday, April 4th. Finally, BTIG Research reissued a “hold” rating on shares of Vital Therapies in a report on Monday, May 28th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy”.
Shares of Vital Therapies traded down $0.93, reaching $7.68, during mid-day trading on Wednesday, according to MarketBeat.com. 363,547 shares of the stock traded hands, compared to its average volume of 248,180. The firm has a market capitalization of $324.12 million, a P/E ratio of -5.86 and a beta of 4.20. Vital Therapies has a 1 year low of $2.42 and a 1 year high of $8.81.
Vital Therapies (NASDAQ:VTL) last released its quarterly earnings results on Tuesday, May 8th. The company reported ($0.34) EPS for the quarter, meeting analysts’ consensus estimates of ($0.34). research analysts forecast that Vital Therapies will post -1.23 earnings per share for the current year.
Vital Therapies Company Profile
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.